Ginkgo Bioworks announces multi-target RNA discovery collaboration with Pfizer

Ginkgo Bioworks (DNA) announced a collaboration with Pfizer (PFE) focused on the discovery of RNA-based drug candidates. In the collaboration, Pfizer will leverage Ginkgo’s proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas. Ginkgo will receive an upfront payment and is eligible to receive research fees and development and commercial milestone payments, up to an aggregate total of $331M across three programs. Ginkgo is entitled to potential further downstream value in the form of royalties on sales.